Galecto | Damora Therapeutics

The company operates within the global biotechnology and life sciences sector, targeting a market comprised of healthcare providers and patients with rare hematologic malignancies. Its business model is centered on a research-heavy approach where value is generated through the progression of novel drug candidates through complex clinical trial phases. As a clinical-stage entity, Damora Therapeutics relies on strategic private placements and public equity offerings to sustain its operations while it works toward the eventual regulatory approval and commercialization of its therapeutic pipeline.

The primary technological focus of the company is the development of DMR-001, a long-acting antibody engineered to target mutant calreticulin (mutCALR), which is a key driver in myeloproliferative neoplasms such as essential thrombocythemia and myelofibrosis. This approach differentiates the company from traditional symptomatic treatments by attempting to address the underlying genetic cause of the disease. By combining its historical expertise in biological pathways with newly acquired assets in antibody engineering, Damora Therapeutics is positioned to deliver targeted therapies that offer broad mutation coverage and improved patient convenience.